INTRODUCTION
============

The popular P2Y~12~ receptor inhibitor, clopidogrel plays an important role in preventing recurrent ischemic events in patients with acute coronary syndrome (ACS) \[[@B1]\]. However, clinical studies have shown that inter-individual variability in the response to clopidogrel may be associated with high residual platelet reactivity (HPR) in patients undergoing percutaneous coronary intervention (PCI) and increases the risk of stent thrombosis \[[@B1][@B2][@B3]\]. Among several factors, genetic polymorphisms affecting the metabolism of clopidogrel play the most important role during the entire metabolic process \[[@B4]\]. On the genetic level, loss-of-function (LOF) variants of the *CYP2C19* gene have been identified as the most prominent contributor to platelet activity after clopidogrel treatment \[[@B5]\].

Recently, various systems for platelet function test have been used to measure platelet reactivity. Current laboratory techniques, such as ADP-induced light transmittance aggregometry (LTA), the VerifyNow P2Y~12~ assay, multiple electrode platelet aggregometry (MEA), and flow cytometry are all based on different principles and measure different properties to evaluate platelet activation \[[@B6][@B7]\]. Another platelet function analyzer (PFA) (INNOVANCE PFA-200 System; Siemens Healthcare, Marburg, Germany) equipped with the new P2Y assay is also being used in clinical trials \[[@B7][@B8]\]. As an improved version of PFA-100, the PFA-200 has now become more usable because it overcame the lack of sensitivity to the effects of clopidogrel and has shown promising results in a few clinical studies \[[@B9][@B10]\]. However, few studies have investigated the sensitivity and specificity of PFA-200 assays for detecting inhibition of platelet function in patients taking oral clopidogrel, based on their *CYP2C19* polymorphism status.

The aim of this study was to evaluate the impact of *CYP2C19* polymorphism on various platelet function tests and the ability to predict the efficacy of antiplatelet treatment, focusing on the newly introduced PFA-200 P2Y test. We also investigated the applicability of *CYP2C19* genotyping to decisions on the direction of treatment, as well as predictions regarding the efficacy of treatment options.

METHODS
=======

1. Study population and patient characteristics
-----------------------------------------------

We enrolled 93 patients who underwent PCI with implantation of drug-eluting stents for the evaluation of platelet reactivity from July 2013 to November 2014. However, 10 patients prematurely discontinued the study owing to early revocation of consent (n=3) or an unwillingness to continue (n=7). Therefore, we could perform *CYP2C19* genotyping on 83 patients. A flow chart of the study design is shown in [Fig. 1](#F1){ref-type="fig"}. Inclusion criteria identified patients between 18 and 80 yr of age with symptomatic ACS including unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI). Those with severe renal failure (creatinine level \>2.5 mg/dL), active internal bleeding or bleeding diathesis, hemodynamic instability, malignancies, contraindications for antiplatelet agents, concomitant use of warfarin or a glycoprotein (GP) IIb/IIIa receptor blocker, thrombocytopenia (platelet count\<0.1×10^6^/L) or anemia (Hb\<8.0 g/dL) were all excluded. The baseline clinical characteristics of the patients are shown in [Table 1](#T1){ref-type="table"}. There were no significant clinical differences among the genotyping subgroups.

Clopidogrel 300-mg loading dose (LD) was administered at least four hours before PCI for patients who had received maintenance antiplatelet therapy comprising aspirin 100 mg and clopidogrel 75 mg for longer than five days. For those who had not received aspirin and clopidogrel antiplatelet maintenance therapy, an LD of clopidogrel 600 mg and 300 mg aspirin was administered at least four hours before PCI. The patients were then administered a maintenance dose of clopidogrel and aspirin (75 mg and 100 mg once daily). Diagnostic procedures and PCI were performed in line with standard practices. The patients underwent *CYP2C19* genotyping once and platelet-function testing before and 24 hr post PCI. The study design was approved by the Institutional Review Board of Dong-A University Hospital, Busan, Korea. Written informed consent was obtained from every patient before enrollment.

2. Platelet function testing
----------------------------

Blood samples for platelet function tests were taken from patients in the catheterization room at pre-loading and were defined as the time between the arrival of the patient at the cardiac catheterization laboratory and the beginning of coronary angiography using a standardized technique through an indwelling arterial sheath into tubes containing 3.2% sodium citrate (Dynabyte, Munich, Germany). Secondary blood sampling from the antecubital vein using a 21-gauge needle was performed the next morning, 24 hr after PCI.

Platelet reactivity was measured by using the INNOVANCE PFA-200 system (Siemens Healthcare), LTA Chrono-log model 560 (Chrono-log Corp, Havertown, PA, USA), and VerifyNow (Accumetrics, San Diego, CA, USA). These assays were performed according to the manufacturers\' instructions. The numerical results of PFA-200 assays were expressed as closure time (sec), LTA as a percentage, and the VerifyNow assay as P2Y~12~ reaction units (PRU).

We also compared the percentage of HPR in each group. We defined HPR as having a PFA-200 assay result of\<193 sec \[[@B11]\], a 10 µmol/L ADP maximum platelet aggregation (MPA) ≥ 55% \[[@B12]\], and VerifyNow P2Y~12~ result \>208 PRU \[[@B13]\].

3. *CYP2C19* genotyping
-----------------------

*CYP2C19* was genotyped by using the Spartan RX *CYP2C19* system (Spartan Bioscience Inc, Ottawa, Canada) according to the manufacturer\'s instructions, as previously described \[[@B14]\]. In brief, we acquired buccal swabs and inserted the samples into the test cartridges of the Spartan RX *CYP2C19* system. The results were categorized into three subgroups: extensive metabolizers (EM, including the *^\*^1/^\*^1* and *^\*^1/^\*^17* diplotypes), intermediate metabolizers (IM, including the *^\*^1/^\*^2* and *^\*^1/^\*^3* diplotypes), and poor metabolizers (PM, including the *^\*^2/^\*^2*, *^\*^3/^\*^3*, and *^\*^2/^\*^3* diplotypes).

4. Statistics analysis
----------------------

The findings for the *CYP2C19* subgroups were compared by using the Chi-square and Kruskal-Wallis tests. Continuous variables were presented as means±SD and compared by using the unpaired t-test. Categorical variables were presented as numbers or percentages and were compared by using Chi-square or Fisher\'s exact tests when the expected frequency was \<5. Pearson\'s correlation coefficient was used to evaluate associations between the results of the PFA-200, LTA, and VerifyNow assay systems. The correlation coefficient was classified into three grades: high correlation (0.5 to 1.0), medium correlation (0.3 to 0.5), and low correlation (0.1 to 0.3) \[[@B15]\]. *P* values \<0.05 were considered statistically significant. Statistical analyses were performed using the SPSS for Windows software package, version 14.0K (SPSS Inc, Chicago, IL, USA).

RESULTS
=======

1. Frequencies of *CYP2C19* genotypes
-------------------------------------

The distribution of *CYP2C19* polymorphisms was 34 (40.9%) for EM, 32 (38.6%) for IM, and 17 (20.5%) for PM. In total, 49 patients (59.0%) were carriers of *CYP2C19^\*^2* or *CYP2C9^\*^3*. The percentage genotype distribution for each allele was consistent with that predicted by Hardy-Weinberg equilibrium for polymorphisms (*P*\>0.05).

2. Platelet function tests in EM, IM, and PM patients
-----------------------------------------------------

The post-procedure PFA-200 values for EM patients (285.3±38.8) were higher than those of IM and PM patients (227.7±98.3 and 133.7±99.2, respectively; *P*=0.024). The post-procedure LTA values for EM patients (24.4±15.7) were lower than those of IM and PM patients (34.1±17.6 and 42.2±16.9, respectively; *P*\<0.001). Using the VerifyNow assay, we also observed lower platelet activity in EM patients than in IM and PM groups (post-procedure; EM: 133.2±60.5, IM: 171.5±42.6, PM: 218.7±59.3, *P*\<0.001; [Fig. 2](#F2){ref-type="fig"}).

Using the criteria reported in the literature \[[@B11][@B12][@B13]\], we also compared the post-procedure HPR rate among different *CYP2C19* phenotypes and platelet function results ([Fig. 3](#F3){ref-type="fig"}). PFA-200 assays showed that the HPR rate significantly differed among the EM, IM, and PM groups (PM:IM:EM=82.4:40.6: 11.8; *P*\<0.001). Similar results were observed for LTA, and we observed a higher HPR rate in the IM and PM groups than that in the EM group (PM:IM:EM=35.3:18.8:5.9; *P*=0.048). We also observed a higher HPR rate in the PM group than the IM and EM groups for the VerifyNow results. However, although HPR rate was higher in the IM group, there was no statistically significant difference compared with the EM group (PM:IM: EM=58.8:21.9:11.8; *P*=0.001).

We also observed a significant correlation between the results for PFA-200 and the other two platelet-function testing systems: r=-0.379 (*P*\<0.001) for PFA-200 and LTA; r=-0.319 (*P*\<0.001) for PFA-200 and VerifyNow assays ([Fig. 4](#F4){ref-type="fig"}).

DISCUSSION
==========

In the present study, we used three platelet function devices including a new generation PFA-200 to evaluate the impact of *CYP2C19* polymorphisms on the clopidogrel response. We observed significantly higher platelet reactivity in certain *CYP2C19* (*^\*^2* and *^\*^3*) allele carriers than that in non-carriers among patients with coronary artery disease (CAD) ([Fig. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). We also observed medium correlations between the results for PFA-200 and other conventional platelet function test devices ([Fig. 4](#F4){ref-type="fig"}).

Clopidogrel is a thienopyridine prodrug that requires processing by two sequential oxidative steps that are mediated by several CYP450 isoenzymes, and only 15% is available for transformation to the active metabolite \[[@B16]\]. Among several CYP enzymes, *CYP2C19* contributes most to its metabolism (being responsible for approximately 45% of the first step and approximately 20% of the final step) and plays an important role in the clinically relevant effects of clopidogrel \[[@B4][@B16]\]. *CYP2C19* variants, particularly *CYP2C19^\*^2* and *^\*^3*, are reproducibly associated with variability in the bioavailability of the active metabolite and the antiplatelet effects of clopidogrel \[[@B17]\].

In the TRITON-TIMI 38 study, patients with the *CYP2C19^\*^2* polymorphism had a 53% increased relative risk of major adverse cardiovascular events \[[@B18]\]. Moreover, the number of the *CYP2C19* LOF alleles in the Korean acute myocardial infarction (AMI) patients has been associated with an increased risk of ischemic events including cardiovascular death, nonfatal MI, and ischemic stroke \[[@B5]\]. In addition, previous studies have shown that *CYP2C19* LOF allele frequencies for *^\*^2* and *^\*^3* are higher in Asian populations (approximately 60%) than in the Caucasian population (approximately 30%) \[[@B3][@B19]\]. Considering the prevalence of the *CYP2C19* LOF allele, the Asian ethnic group may increase the level of platelet reactivity and the prevalence of HPR than Caucasian groups when given the same oral dose of clopidogrel. These findings suggest that testing for *CYP2C19* polymorphisms should be applicable to CAD patients when using clopidogrel antiplatelet therapy, particularly in East Asian patients.

Various platelet function tests have been used to evaluate platelet reactivity after the administration of aspirin and clopidogrel in large trials. Among those techniques, LTA, VerifyNow, flow cytometry, and MEA are the most commonly used platelet function tests. LTA is the traditional technique used to evaluate platelet activity and has been regarded as the classical method for many years. As a turbidimetric-based, optical detection point-of-care device, the VerifyNow system uses cartridges that contain different agonists to activate the platelets. The test is very easy to perform, and results are reproducible and quickly available. All the above characteristics have led to its use in many clinical trials, and it showed a very good correlation with LTA results \[[@B20][@B21][@B22]\]. In our study, we used LTA and VerifyNow platelet function assessment methods and could find evidence for a significant association between the efficacy of clopidogrel and the *CYP2C19* genotypes. In addition, we observed a higher HPR rate in the IM and PM groups ([Fig. 3](#F3){ref-type="fig"}).

We also evaluated the novel platelet function evaluation device, PFA-200 in the Korean population. PFA-200 has several advantages: it is easy to use, automated, and rapid, and mimics several characteristics of physiologic platelet function \[[@B10]\]. In a previous study, use of the PFA-100 collagen/ADP assay did not reveal a significant correlation between the HPR (cut-off value of 236 sec) and clinical outcomes including all-cause death, nonfatal AMI, stent thrombosis, and ischemic stroke \[[@B23]\]. However, another clinical study has demonstrated that platelet reactivity above a threshold of 193 sec using PFA-100 is associated with a higher risk of adverse ischemic events \[[@B8][@B11]\]. A few studies have demonstrated that the PFA-200 system has good sensitivity and specificity for testing platelet function compared with the previous generation of PFA-100 \[[@B8]\]. In the present study, compared to the other platelet function tests, PFA-200 system showed notable differences in the platelet functions at post-PCI among the EM, IM, and PM groups ([Fig. 2](#F2){ref-type="fig"}). We also observed that results of PFA-200 medium correlated with those of other conventional platelet-function test devices. By defining cut-off values for HPR (\<193) using PFA-200, we observed statistically significant differences in the HPR rate among the EM, IM, and PM groups (PM:IM:EM=82.4:40.6:11.8; *P*\<0.001) ([Fig. 3](#F3){ref-type="fig"}). However, because PFA-200 still has a maximum value of 300 sec, any correlation with other tests lacked smoothness. To the best of our knowledge, the use of the PFA-200 device for measuring platelet function has still been limited to small-scale trials with few patients. Further evaluation of the sensitivity, specificity, and practicality of the platelet function assay using PFA-200 requires more clinical trials with greater number of patients.

Finally, we need further follow-up of patients to determine correlations between clinical events and HPR defined using PFA-200 assays.

The study limitations were that the active metabolites of clopidogrel were not analyzed according to the presence of *CYP2C19* polymorphisms and we did not verify correlations between the *CYP2C19* polymorphisms and clinical outcomes.

In the present study, about 59.0% of Korean patients with cardiovascular disease receiving clopidogrel had *CYP2C19* polymorphisms classified as IM or PM, and the frequency was similar to previously reported data from Asian populations. We also found evidence for a significant association between the efficacy of clopidogrel and *CYP2C19* genotypes using PFA-200 platelet function tests.
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![Study flow diagram.\
Abbreviations: PCI, percutaneous coronary intervention; EM, extensive metabolizers; IM, intermediate metabolizers; PM, poor metabolizers; LTA, light transmittance aggregometry.](alm-36-42-g001){#F1}

![The platelet function test values for three different devices, measured post-percutaneous coronary intervention (PCI). (A) PFA-200 (sec); (B) Light transmittance aggregometry (LTA, %); (C) VerifyNow (PRU). Error bars indicate SD.\
Abbreviations: EM, extensive metabolizers; IM, intermediate metabolizers; PM, poor metabolizers; PRU, P2Y12 reaction unit.](alm-36-42-g002){#F2}

![The percentage of high platelet reactivity (HPR) measured post-percutaneous coronary intervention (PCI) in different groups. (A) PFA-200; (B) Light transmittance aggregometry (LTA); (C) VerifyNow.](alm-36-42-g003){#F3}

![Relationships between the results obtained by using PFA-200 (sec) and light transmittance aggregometry (LTA, %) or VerifyNow (PRU) assay systems post-percutaneous coronary intervention (PCI). Correlation coefficient (r) was calculated by using Pearson\'s method.\
Abbreviation: PRU, P2Y12 reaction unit.](alm-36-42-g004){#F4}

###### Demographics of the study population

![](alm-36-42-i001)

  Variable                          Overall        EM             IM             PM             *P* value
  --------------------------------- -------------- -------------- -------------- -------------- -----------
  Age (yr), mean±SD                 63.76±10.05    63.56±9.74     64.22±9.26     63.29±12.45    0.945
  Male gender, N (%)                58 (69.9)      27 (79.4)      23 (71.9)      8 (47.1)       0.057
  Riskfactors                                                                                   
   Hypertension, N (%)              47 (56.6)      22 (64.7)      15 (46.9)      10 (58.8)      0.337
   Diabetic mellitus, N (%)         29 (34.9)      13 (38.2)      10 (31.2)      6 (35.3)       0.837
   Dyslipidemia, N (%)              13 (15.7)      7 (20.6)       4 (12.5)       2 (11.8)       0.588
   Chronic kidney disease, N (%)    8 (9.6)        4 (11.8)       2 (6.2)        2 (11.8)       0.709
   Current smoking, N (%)           9 (10.8)       2 (5.9)        5 (15.6)       2 (11.8)       0.441
  BMI (kg/m^2^)                     24.84±3.0      24.24±3.08     25.52±2.47     24.77±3.61     0.222
  Past history                                                                                  
   Previous PCI, N (%)              33 (39.8)      14 (41.2)      13 (40.6)      6 (35.3)       0.914
   Previous MI, N (%)               12 (14.5)      3 (8.8)        6 (18.8)       3 (17.6)       0.475
   Previous stroke, N (%)           3 (3.6)        1 (2.9)        1 (3.1)        1 (5.9)        0.853
   Previous CABG, N (%)             1 (1.2)        0 (0.0)        1 (3.1)        0 (0.0)        0.446
  Medication                                                                                    
   Statin, N (%)                    49 (59.0)      22 (64.7)      18 (56.2)      9 (52.9)       0.665
   Calcium channel blocker, N (%)   38 (45.8)      11 (32.4)      19 (59.4)      8 (47.1)       0.088
   Beta-blocker, N (%)              46 (55.4)      18 (52.9)      17 (53.1)      11 (64.7)      0.689
   ACEI, N (%)                      9 (10.8)       2 (5.9)        4 (12.5)       3 (17.6)       0.413
   ARB, N (%)                       10 (12.0)      3 (8.8)        4 (12.5)       3 (17.6)       0.656
   Nitrate, N (%)                   54 (65.1)      19 (55.9)      24 (75.0)      11 (64.7)      0.266
   Diuretics, N (%)                 11 (13.3)      4 (11.8)       3 (9.4)        4 (23.5)       0.360
  LVEF %                            57.26±8.75     56.83±9.66     57.50±8.60     57.67±7.53     0.943
  Hemoglobin (g/dL)                 13.27±2.41     13.19±2.97     13.62±1.96     12.77±1.92     0.501
  Creatinine (mg/dL)                1.42±1.74      1.44±2.12      1.39±1.62      1.43±1.10      0.993
  Platelet count (10^9^/L)          209.95±45.42   208.09±48.18   211.47±42.48   210.81±48.06   0.954

Continuous data are shown as mean±SD, Dichotomous data are shown as N (%).

Abbreviations: EM, extensive metabolizers; IM, intermediate metabolizers; PM, poor metabolizers; LVEF, left ventricular ejection fraction; BMI, body mass index; PCI, percutaneous coronary intervention; MI, myocardial infarction; CABG, coronary artery bypass grafting; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
